MX2024014232A - Anticuerpo anti-b7h3 y usos del mismo - Google Patents

Anticuerpo anti-b7h3 y usos del mismo

Info

Publication number
MX2024014232A
MX2024014232A MX2024014232A MX2024014232A MX2024014232A MX 2024014232 A MX2024014232 A MX 2024014232A MX 2024014232 A MX2024014232 A MX 2024014232A MX 2024014232 A MX2024014232 A MX 2024014232A MX 2024014232 A MX2024014232 A MX 2024014232A
Authority
MX
Mexico
Prior art keywords
antibody
antigen
methods
binding portion
binds
Prior art date
Application number
MX2024014232A
Other languages
English (en)
Spanish (es)
Inventor
Naiyan Rong
Zhuozhi Wang
Jie Li
Jijie Gu
Original Assignee
Wuxi Biologics Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics Ireland Ltd filed Critical Wuxi Biologics Ireland Ltd
Publication of MX2024014232A publication Critical patent/MX2024014232A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2024014232A 2022-05-18 2024-11-15 Anticuerpo anti-b7h3 y usos del mismo MX2024014232A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022093524 2022-05-18
PCT/CN2023/094711 WO2023222017A1 (en) 2022-05-18 2023-05-17 Anti-b7h3 antibody and uses thereof

Publications (1)

Publication Number Publication Date
MX2024014232A true MX2024014232A (es) 2025-03-07

Family

ID=88834684

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024014232A MX2024014232A (es) 2022-05-18 2024-11-15 Anticuerpo anti-b7h3 y usos del mismo

Country Status (12)

Country Link
US (1) US20250313633A1 (enExample)
EP (1) EP4526346A1 (enExample)
JP (1) JP2025517737A (enExample)
KR (1) KR20250011957A (enExample)
CN (1) CN119256010A (enExample)
AU (1) AU2023273853A1 (enExample)
CA (1) CA3253563A1 (enExample)
CL (1) CL2024003486A1 (enExample)
IL (1) IL316510A (enExample)
MX (1) MX2024014232A (enExample)
TW (1) TW202402808A (enExample)
WO (1) WO2023222017A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118829656B (zh) * 2023-12-01 2026-04-24 苏州智核生物医药科技有限公司 B7h3结合多肽及其用途
WO2025157244A1 (zh) * 2024-01-25 2025-07-31 山东先声生物制药有限公司 抗b7h3抗体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
AU2015306621B2 (en) * 2014-08-27 2021-05-06 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses
UA125593C2 (uk) * 2017-03-31 2022-04-27 Джянгсу Хенгруй Медісін Ко., Лтд. Антитіло в7-н3, його антигензв'язуючий фрагмент та його медичне застосування
KR102732027B1 (ko) * 2019-07-09 2024-11-20 주식회사 와이바이오로직스 B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
CN112851812B (zh) * 2020-06-30 2021-09-14 广州百暨基因科技有限公司 抗b7h3抗体及其应用
CN113402610B (zh) * 2021-06-09 2023-02-24 英诺湖医药(杭州)有限公司 一组b7h3单克隆抗体及其医药用途
CN113336851B (zh) * 2021-06-30 2021-12-24 徐州医科大学 新型全人源抗人b7h3抗体、包含所述抗体的组合物及其应用

Also Published As

Publication number Publication date
CA3253563A1 (en) 2023-11-23
CL2024003486A1 (es) 2025-06-13
WO2023222017A1 (en) 2023-11-23
US20250313633A1 (en) 2025-10-09
CN119256010A (zh) 2025-01-03
JP2025517737A (ja) 2025-06-10
TW202402808A (zh) 2024-01-16
AU2023273853A1 (en) 2024-10-24
EP4526346A1 (en) 2025-03-26
KR20250011957A (ko) 2025-01-22
IL316510A (en) 2024-12-01

Similar Documents

Publication Publication Date Title
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
DE602006013029D1 (de) Anti-egfr-antikörper
TN2019000272A1 (en) Anti-ilt4 antibodies and antigen-binding fragments.
MX2024002238A (es) Anticuerpos anti-ccr8 y uso de los mismos.
PH12019501929A1 (en) Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
MX2023010499A (es) Anticuerpos heterodimericos que se unen a cd3 y cldn6.
ZA202208337B (en) A bispecific anti-pd-l1/vegf antibody and uses thereof
ZA202213434B (en) Anti-lilrb1 antibody and uses thereof
MX2021002750A (es) Anticuerpos anti-tnfrsf9 y usos de los mismos.
PH12022552725A1 (en) Anti-ox40 antibody and uses thereof
WO2020218951A3 (ru) Моноклональное антитело, которое специфически связывается с gitr
PH12022553035A1 (en) Anti-phf-tau antibodies and uses thereof
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
ZA202309150B (en) Antibody against nkp46 and application of antibody
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
CL2024003486A1 (es) Anticuerpo anti-b7h3 y usos del mismo
MY208387A (en) Antibodies specifically recognizing pseudomonas pcrv and uses thereof
WO2019224385A3 (en) Combined bispecific antibody and immuno-oncology therapies
PH12021550991A1 (en) Monoclonal antibody that specifically binds to cd20
PH12022552558A1 (en) Humanized anti-complement factor bb antibodies and uses thereof
MX2025009475A (es) Anticuerpo anti-cntn4 y usos de este
WO2020237092A3 (en) Mmp-9 antibodies and methods of use thereof
WO2020005934A8 (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof